Physician profile
Lance Barton
NPI 1427085851
$13,908.08
in general payments reported to CMS, 2019-2025
47 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $2,222 · 2021: $2,625 · 2022: $1,768 · 2023: $1,556 · 2024: $2,274 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,256 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,256.19 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,935.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,933.86 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,146.17 | 2019-2025 | |
| Novo Nordisk INC | $1,039.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,002.68 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $958.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $864.88 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $787.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.17 | 2019-2024 | Jardiance |
| Abbott Laboratories | $391.02 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Allergan, INC. | $371.99 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $336.58 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.28 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $244.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $232.02 | 2019-2024 | Xarelto |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.